BCTXZ

BriaCell Therapeutics Corp. Warrant

1.15 USD
+0.03
2.68%
Updated May 21, 1:30 PM EDT
1 day
2.68%
5 days
15.00%
1 month
-12.21%
3 months
-12.21%
6 months
-12.21%
Year to date
-12.21%
1 year
-12.21%
5 years
-12.21%
10 years
-12.21%
 

About: BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Employees: 12

Funds holding %
of 7,202 funds
Analysts bullish %

Fund manager confidence

Research analyst outlook

We haven’t received any recent analyst ratings for BCTXZ.

Financial journalist opinion

We haven’t received any recent news articles for BCTXZ.

Charts implemented using Lightweight Charts™